As of close of business last night, Hookipa Pharma Inc’s stock clocked out at $0.76, down -3.37% from its previous closing price of $0.79. On the day, 665544 shares were traded.
Ratios:
To gain a deeper understanding of HOOK’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.50 and its Current Ratio is at 3.50. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.04.
Morgan Stanley Downgraded its Overweight to Equal-Weight on November 12, 2021, while the target price for the stock was maintained at $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 21 ’23 when Kandera Reinhard bought 7,000 shares for $0.72 per share. The transaction valued at 5,075 led to the insider holds 43,092 shares of the business.
Kandera Reinhard bought 8,000 shares of HOOK for $5,712 on Aug 16 ’23. The Chief Financial Officer now owns 36,092 shares after completing the transaction at $0.71 per share. On Jul 11 ’23, another insider, Aldag Jorn, who serves as the Chief Executive Officer of the company, bought 5,000 shares for $0.83 each. As a result, the insider paid 4,142 and bolstered with 71,952 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.74 while its Price-to-Book (P/B) ratio in mrq is 0.84.
Stock Price History:
Over the past 52 weeks, HOOK has reached a high of $2.05, while it has fallen to a 52-week low of $0.41.
Shares Statistics:
A total of 96.55M shares are outstanding, with a floating share count of 70.37M. Insiders hold about 28.89% of the company’s shares, while institutions hold 35.31% stake in the company.
Earnings Estimates
As of right now, Robinhood Markets, Inc. analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.76, with high estimates of $18.46 and low estimates of $2.11.
Analysts are recommending an EPS of between $Consumer Cyclical and $Consumer Cyclical for the fiscal current year, implying an average EPS of $Healthcare.
